Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

October 22, 2024 M&A

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.

The participating investors were the existing shareholder Invus, as well as one or more funds under the management of Capital Group, a new investor in Vicore.
Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's shares are listed on Nasdaq Stockholm.

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

Related

Vinge advises Platzer in conjunction with the sale of a school property in Gothenburg

Vinge has advised Platzer Fastigheter AB in connection with the sale of a school property situated in Södra Änggården, Gothenburg. The property, which was sold as a corporate transaction, has a value of SEK 552 million. The sale is part of Platzer's strategy to develop and optimise its property portfolio.
January 17, 2025

Vinge advises Qben Infra in connection with issuance of senior, unsecured bonds and early redemption

Vinge has advised Qben Infra AB in connection with its issuance of senior, unsecured bonds in an amount of SEK 500,000,000 (within a framework of SEK 600,000,000) and the parallel early redemption by its subsidiary ININ Group AS in respect of its previously issued senior secured bonds due 2027.
January 16, 2025

Vinge Represents Ellevio in the Acquisition of Markbygden Net Väst AB

Vinge represents Ellevio in the acquisition of Markbygden Net Väst AB, a network company that connects to the national grid via Svenska kraftnät's station in Trolltjärn outside Arvidsjaur, from Enercon.
January 16, 2025